Application of (89)Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody

PURPOSE: The recent conditional FDA approval of Aducanumab (Adu) for treating Alzheimer’s disease (AD) and the continued discussions around that decision have increased interest in immunotherapy for AD and other brain diseases. Reliable techniques for brain imaging of antibodies may guide decision-m...

Descripción completa

Detalles Bibliográficos
Autores principales: Stergiou, N., Wuensche, T. E., Schreurs, M., Mes, I., Verlaan, M., Kooijman, E. J. M., Windhorst, A. D., Helboe, L., Vergo, S., Christensen, S., Asuni, A. A., Jensen, A., Van Dongen, G. A. M. S., Bang-Andersen, B., Vugts, D. J., Beaino, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027647/
https://www.ncbi.nlm.nih.gov/pubmed/36635462
http://dx.doi.org/10.1007/s00259-023-06109-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027647/
https://www.ncbi.nlm.nih.gov/pubmed/36635462
http://dx.doi.org/10.1007/s00259-023-06109-3

Ejemplares similares